West Pharmaceutical Services Inc. (WST) to Issue Quarterly Dividend of $0.15 on November 7th

West Pharmaceutical Services Inc. (NYSE:WST) announced a quarterly dividend on Thursday, May 3rd, NASDAQ reports. Shareholders of record on Wednesday, October 24th will be given a dividend of 0.15 per share by the medical instruments supplier on Wednesday, November 7th. This represents a $0.60 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Tuesday, October 23rd. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.14.

West Pharmaceutical Services has increased its dividend by an average of 8.9% annually over the last three years and has raised its dividend every year for the last 25 years. West Pharmaceutical Services has a dividend payout ratio of 19.9% indicating that its dividend is sufficiently covered by earnings. Research analysts expect West Pharmaceutical Services to earn $3.22 per share next year, which means the company should continue to be able to cover its $0.56 annual dividend with an expected future payout ratio of 17.4%.

WST stock opened at $118.93 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.67 and a quick ratio of 1.94. West Pharmaceutical Services has a 52-week low of $82.74 and a 52-week high of $125.09. The stock has a market cap of $9.08 billion, a price-to-earnings ratio of 42.78, a PEG ratio of 4.19 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.03. West Pharmaceutical Services had a net margin of 8.99% and a return on equity of 15.38%. The company had revenue of $447.50 million during the quarter, compared to analysts’ expectations of $422.57 million. During the same period in the prior year, the company earned $0.66 earnings per share. The business’s quarterly revenue was up 12.6% compared to the same quarter last year. As a group, equities analysts anticipate that West Pharmaceutical Services will post 2.82 EPS for the current fiscal year.

In other West Pharmaceutical Services news, SVP Karen Flynn sold 20,458 shares of the company’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total transaction of $2,377,833.34. Following the completion of the sale, the senior vice president now directly owns 31,051 shares in the company, valued at $3,609,057.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by corporate insiders.

WST has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $110.50.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Story: Analyzing a company’s cash flow statement

Dividend History for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply